Latest News and Press Releases
Want to stay updated on the latest news?
-
SUNRISE, Fla., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today it has appointed a five-member Advisory Board comprised of local and international business, financial and...
-
SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell™ at...
-
SUNRISE, Fla., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Bioheart (BHRT.OB), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that they have been chosen as a...
-
SUNRISE, Fla., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that it has acquired the worldwide exclusive rights to Ageless Regenerative Institute's adipose (fat) derived...
-
SUNRISE, Fla., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Bioheart (OTCBB:BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that Frank Young will join Bioheart...
-
SUNRISE, Fla., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB), a company focused on developing stem cell therapies for heart disease announced that they have entered into an agreement with...
-
SUNRISE, Fla., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that they have completed an Investigational New Drug (IND) application to the FDA for the ANGEL trial. The clinical...
-
SUNRISE, Fla., Nov. 15, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) a leader in the field of stem cell therapy for the treatment of damaged hearts, today announced that it entered into a $3M...
-
SUNRISE, Fla., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) today released a short clip from the American Investor Documentary. William P. Murphy Jr., MD talks about the unrealized...
-
SUNRISE, Fla., Oct. 18, 2011 (GLOBE NEWSWIRE) -- www.bioheartinc.com/">Bioheart, Inc. (OTCBB:BHRT) was among top scientists and physicians presenting cutting edge data at the Controversies and...